Understanding how ovarian cancer spreads and resists treatment
Metabolic reprogramming of the tumor microenvironment and therapy resistance
This study is looking at how metastatic ovarian cancer spreads and why it sometimes doesn't respond to chemotherapy, focusing on how fat tissue around the tumor affects cancer growth and treatment, with the hope of finding better ways to help patients fight this tough disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10889164 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind the spread of metastatic ovarian cancer and its resistance to chemotherapy. It focuses on how the tumor microenvironment, particularly the role of adipose tissue, influences cancer progression and treatment outcomes. By studying the metabolic changes in cancer cells and their interactions with surrounding cells, the research aims to identify potential targets for improving therapy effectiveness. Patients may benefit from insights that could lead to new treatment strategies tailored to combat this aggressive cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic ovarian cancer, particularly those experiencing treatment resistance.
Not a fit: Patients with early-stage ovarian cancer or those whose cancer has not metastasized may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for metastatic ovarian cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promising results in understanding tumor microenvironments and their impact on cancer treatment, suggesting that this approach could yield valuable insights.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Lengyel, Ernst — University of Chicago
- Study coordinator: Lengyel, Ernst
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.